Abstract
To determine whether adjuvant treatment (AT: hormonal or radiation) affects outcome in pathologic Stage T3 (pT3) prostate cancer when analyzed according to DNA ploidy. The predictive value of nuclear DNA ploidy and AT on clinical and prostate-specific antigen (PSA) progression and on overall and cause-specific survival after radical retropubic prostatectomy was assessed in 894 patients with pT3 prostate cancer. Mean follow-up was 6.7 years (range, 0.3 to 20). Mean age was 66 years (range, 39 to 79). Six hundred sixty patients (74%) had no immediate AT, 131 (15%) had early adjuvant radiotherapy (ART), and 103 (12%) had early adjuvant orchiectomy (AHT). DNA diploid tumors were found in 445 patients (52%), tetraploid tumors in 346 (41%), and aneuploid tumors in 59 (7%). DNA ploidy was a significant (P < 0.05) prognostic indicator for clinical systemic progression-free survival. With PSA progression (more than 0.2 ng/mL) as an endpoint, ploidy was an even more powerful predictor for outcome (P = 0.004). Use of early AHT or ART was associated with decreased overall clinical progression for diploid and nondiploid tumors (P < 0.001 and P < 0.001, respectively). With respect to PSA progression, ART and AHT were equally effective and su...Continue Reading
References
Jul 1, 1992·Cancer·H ZinckeN J Gonchoroff
Aug 1, 1989·Mayo Clinic Proceedings·O NativM M Lieber
Sep 15, 1969·JAMA : the Journal of the American Medical Association·D C Utz, G M Farrow
Nov 1, 1983·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·D W HedleyE A Musgrove
Jun 1, 1993·Cancer·J I EpsteinP C Walsh
Sep 1, 1993·Urology·W S ChengH Zincke
Citations
Jun 8, 2001·Cancer·T J SeboH Zincke
Feb 15, 2005·International Journal of Radiation Oncology, Biology, Physics·Carlos VargasAlvaro A Martinez
Jan 1, 1997·Urology·M J vander KooyM L Blute
Mar 1, 1997·Urology·R S PruthiT A Stamey
Sep 4, 1999·Urology·M T GettmanD G Bostwick
Oct 10, 2001·The Urologic Clinics of North America·S E Schild, T M Pisansky
Feb 19, 2002·International Journal of Radiation Oncology, Biology, Physics·Richard ChooAileen Flavin
May 15, 2002·Critical Reviews in Oncology/hematology·Ulka Vaishampayan, Maha Hussain
Dec 25, 2003·Urologic Oncology·David S DiMarcoThomas J Sebo
Mar 27, 2002·The American Journal of Surgical Pathology·Thomas J SeboHorst Zincke
Mar 11, 2010·Current Opinion in Urology·Robert L Grubb, Adam S Kibel
Jul 8, 2008·European Urology·Ute GanswindtClaus Belka
Dec 18, 2001·The Journal of Urology·Weber K LauHorst Zincke
Dec 8, 2009·Cancer Cell·Darren J BakerJan M van Deursen
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PollackW U Shipley
Nov 7, 2001·The Journal of Urology·H ZinckeM L Blute
Feb 1, 1997·The Journal of Urology·H Zincke
Oct 5, 2001·The Journal of Urology·W K LauH Zincke
Mar 29, 2000·The Journal of Urology·B C LeibovichH Zincke
Nov 6, 2010·BJU International·David S YeeJames A Eastham
Nov 11, 2005·The Journal of Urology·Liang ChengMichael O Koch
Feb 10, 2004·The Journal of Urology·Shahrokh F ShariatClaus G Roehrborn
Jul 16, 2005·Scandinavian Journal of Urology and Nephrology. Supplementum·Jonathan I EpsteinRodolfo Montironi
Dec 18, 2012·Cancer Research·Rolando CuevasStefan Duensing
Jul 13, 2005·Mayo Clinic Proceedings·Thomas M Pisansky